Agilent Technologies (A)
Provides analytical instruments, diagnostics, consumables, software, and services for laboratory workflows.
Something off on this page? Send us feedback.
Sells chromatography and mass-spectrometry systems, pathology and genomics tools, laboratory software, consumables, services, and specialty pharmaceutical manufacturing to research, clinical, and industrial labs. Three segments span life sciences and diagnostics, vendor-neutral CrossLab support, and applied testing, linking instrument placements to ongoing service and consumables demand.
Supplies laboratory instruments, software, consumables, and services across three segments. Life Sciences and Diagnostics Markets combines liquid chromatography and mass spectrometry, cell analysis, pathology and companion diagnostics, genomics, and specialty pharmaceutical manufacturing. Agilent CrossLab provides vendor-neutral maintenance, columns and supplies, laboratory automation, and OpenLab informatics. Applied Markets centers on gas chromatography, spectroscopy, vacuum systems, and refurbished instruments for food, environmental, chemical, materials, and forensic testing.
Serves pharmaceutical and biotechnology companies, clinical laboratories, academia, government, and industrial testing customers across the Americas, Europe, and Asia Pacific. Breadth across instruments and vendor-neutral CrossLab support ties consumables, service, and software to installed laboratory workflows. Instrument demand depends on customer capital budgets; diagnostic products require regulatory approvals, and manufacturing and research sites span the United States, Europe, and Asia.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Target | Target: $180 | Target: $165 |
| Sep 2, 2026 | Jefferies | Target | Target: $130 | Target: $155 |
| Aug 27, 2026 | Wells Fargo | Reiterate | Rating: —Target: $160 | Target: $180 |
| Aug 27, 2026 | Barclays | Reiterate | Rating: —Target: $140 | Target: $175 |
| Aug 27, 2026 | RBC Capital | Reiterate | Rating: —Target: $180 | Target: $185 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $1.76B · Total debt $3.95B · Total assets $13.97B · Shareholders' equity $7.36B
- Revenue
- $1.88B
- Operating income
- $444.0M
- Net income
- $362.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 93.42% | 263.84M shares | |
|---|---|---|---|
| 1,165 holders · as of Jun 30, 2026 | |||
| Insiders | 0.30% | 835.8K shares | |
| 27 holders · as of Sep 10, 2026 | |||
| Other | 6.28% | 17.75M shares | |
| remainder | |||
282.43M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.06% | 25.60M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 18.45M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.11% | 14.44M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.55% | 12.85M | as of Jun 30, 2026 |
Massachusetts Financial Services Co /MA/Institution | 3.54% | 10.01M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Mikael Dolsten | director | −634 | $151.38 |
| May 29, 2026 | Mikael Dolsten | director | −1,600 | $135.42 |
| Dec 1, 2025 | Mikael Dolsten | director | −2,600 | $149.81 |
| Nov 26, 2025 | Rodney Gonsalves | officer: V.P., Corporate Controller | −3,000 | $154.99 |
| Nov 18, 2025 | Padraig Mcdonnell | director, officer: President and CEO | −911 | $143.24 |
- Danaher
Broadest-overlap mega-peer: LC-MS, IHC pathology, and cell biology tools.
- Thermo Fisher Scientific
Dominant broad-platform rival in LC, MS, genomics, cell biology, and IHC.
- Waters
Most direct HPLC and LC-MS rival; ~40% global HPLC share; pharma QC-dominant.
- Bruker
Named 10-K rival in MS, NMR, and spectroscopy; expanding into spatial biology.
- Revvity
Multi-segment rival: analytical instruments, immunoassay, genomics, and imaging.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Agilent Technologies | $166.28 | +2.68% | $45.75B | 31.9 | 25.3 | 6.2 | +8.1% |
| Danaher | $221.51 | +2.62% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $661.47 | +0.41% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| Waters | $432.74 | +2.08% | $41.62B | 105.7 | 27.7 | 9.0 | +113.3% |
| Bruker | $62.33 | +1.22% | $9.37B | — | 27.5 | 2.7 | +5.2% |
| Revvity | $144.36 | +0.54% | $16.02B | 68.4 | 25.6 | 5.5 | −1.3% |
| Median | 53.3 | 25.6 | 5.5 | +5.5% |